A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies-Reference-Cited by-同舟云学术

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies

Published:2022-04-05 Issue:2 Volume:3 Page:492-506
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Sharman Jeffrey P.¹,Biondo Juliana M. L.²,Boyer Michelle³,Fischer Kirsten⁴,Hallek Michael⁴,Jiang Dingfeng⁵,Kater Arnon P.⁶,Porro Lurà Michele⁷,Wierda William G.⁸

Affiliation:

1. Department of Medical Oncology Willamette Valley Cancer Institute and Research Center/US Oncology Research Eugene Oregon USA

2. Genentech, Inc. South San Francisco California USA

3. Roche Products Limited Welwyn Garden City UK

4. University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf Germany

5. AbbVie North Chicago Illinois USA

6. Department of Hematology Cancer Center Amsterdam Lymphoma and Myeloma Center Amsterdam Amsterdam University Medical Centers Amsterdam the Netherlands

7. F. Hoffmann‐La Roche Ltd Basel Switzerland

8. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.427

Reference61 articles.

1. Chronic lymphocytic leukaemia

2. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

3. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia